ARCHIMED Acquires Esperion Therapeutics for $1.1 Billion

ARCHIMED, a healthcare-focused investment firm, has entered into a definitive agreement to acquire Esperion Therapeutics for up to $1.1 billion. Esperion, a biopharmaceutical company specializing in cardiometabolic and rare disease therapies, will be purchased with funds managed by ARCHIMED. Shareholders of Esperion will receive $3.16 per share in cash, alongside potential future milestone payments linked to achievement in sales.

The acquisition terms stipulate that Esperion’s shareholders will receive an immediate payout, representing a 58% premium over the company’s closing stock price as of April 30, 2026. This includes contingent value rights (CVRs) tied to specific sales goals that could increase the deal value by $100 million. These milestones include a potential $40 million payment if annual sales of products containing bempedoic acid surpass $350 million in 2027, and a $60 million payment if products containing bumetanide achieve $160 million in sales by the end of 2030.

Esperion has focused on providing solutions for cardiovascular disease, a leading global health challenge. The acquisition is positioned as an opportunity to advance Esperion’s ambitious Vision 2040 strategy, leveraging ARCHIMED’s resources to enhance growth within the cardiovascular market. Esperion CEO Sheldon Koenig noted the transaction aligns with shareholder interests by delivering immediate value and future growth potential.

ARCHIMED’s acquisition of Esperion underscores the firm’s strategy to invest in companies with strong positions in healthcare markets, particularly within cardiovascular and primary care sectors. ARCHIMED Partner Justin Bateman emphasized the strategic alignment and growth potential stemming from the acquisition, noting that Esperion is poised for expansion.

The transaction is endorsed by Esperion's Board of Directors and is subject to customary closing conditions, including shareholder approval. It is anticipated to be finalized in the third quarter of 2026. The acquisition could influence market competitors by consolidating ARCHIMED’s position in the biopharmaceutical space, possibly prompting further activity in cardiometabolic-focused investments or mergers.